- |||||||||| Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Enrollment change: 30g vs 33g Needle for Intravitreal Injections (clinicaltrials.gov) - Jul 24, 2017 P=N/A, N=50, Completed, Active, not recruiting --> Completed Recruiting --> Completed | N=100 --> 50
- |||||||||| Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Phase II Combination Steroid and Anti-VEGF for Persistent DME (clinicaltrials.gov) - Jul 12, 2017 P2, N=129, Completed, Recruiting --> Completed | N=100 --> 50 Recruiting --> Completed
- |||||||||| Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Trial primary completion date: OPHTH-010915: Aflibercept in Recurrent or Persistent CNV (clinicaltrials.gov) - May 30, 2017 P=N/A, N=80, Recruiting, Recruiting --> Active, not recruiting N=20 --> 80 | Trial primary completion date: Dec 2016 --> Dec 2018
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Efficacy and Safety of Lucentis (clinicaltrials.gov) - May 4, 2017 P4, N=21, Completed, Recruiting --> Active, not recruiting | N=150 --> 226 Active, not recruiting --> Completed
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Trial completion, Combination therapy, Monotherapy: EVEREST II: Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) (clinicaltrials.gov) - May 4, 2017 P4, N=321, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial primary completion date: The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study (clinicaltrials.gov) - Mar 31, 2017 P2, N=126, Completed, Trial primary completion date: Nov 2016 --> Apr 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2008 --> Aug 2010
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Trial primary completion date: Ranibizumab Treatment for Retinal Vein Occlusion (clinicaltrials.gov) - Mar 10, 2017 P=N/A, N=100, Recruiting, Recruiting --> Active, not recruiting Trial primary completion date: Sep 2016 --> Sep 2019
|